Contribute Try STAT+ Today

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. And here is a plug: You may also want to stop by the STAT Summit to catch up on insights and developments. We look forward to seeing you. Meanwhile, here are the latest tidbits. Hope your day goes well, and stay safe — wear a mask. …

Pfizer (PFE) and BioNTech (BNTX) announced that the efficacy portion of their Covid-19 vaccine trial has been completed, showing the vaccine to prevent 95% of cases of the disease, STAT writes. The companies plan to submit to the Food and Drug Administration for an emergency use authorization “within days,” and will also submit to regulatory agencies around the globe. The results come little more than a week after the companies said an earlier analysis from the study showed the vaccine reduced infections by more than 90%.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May one observe that Pfizer’s efficacy claims / press releases are hopeful BUT what about the safety aspect? The evidence that I believe was to need another 2 months? Of course I may be confusing different stories in the press – which seems to be all that we have at the moment.
    I believe the criteria used to be “Safety and Efficacy” – in that order? (Emphasis on ‘used to be.’)

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy